Compare $MNPR vs $NGNE | Chartloom

Compare

$MNPR vs $NGNE

Monopar Therapeutics Inc · Neurogene Inc

MNPR

Monopar Therapeutics Inc

NGNE

Neurogene Inc

Compare $MNPR vs $NGNE

Comparing Monopar Therapeutics Inc and Neurogene Inc

MNPRMonopar Therapeutics Inc

NGNENeurogene Inc

MNPRMonopar Therapeutics Inc

Market cap

$529M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

48.37x

Rev growth (TTM)

—

YTD performance

19.6%

52W performance

-19.9%

FCF yield

-2.3%

NGNENeurogene Inc

Market cap

$521M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

31.0%

52W performance

2.2%

FCF yield

-16.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

MNPR

NGNE

Detailed metrics comparison

MNPR

Monopar Therapeutics Inc

NGNE

Neurogene Inc

Market Cap

MNPR$529M

NGNE$521M

Enterprise Value

MNPR$476M

NGNE$409M

Price

MNPR$78.96

NGNE$26.40

P/E Ratio

MNPRN/A

NGNEN/A

P/S Ratio

MNPR0.00x

NGNE0.00x

EV/Sales

MNPR0.00x

NGNE0.00x

EV/EBITDA

MNPR0.00x

NGNE0.00x

P/B Ratio

MNPR4.00x

NGNE2.36x

P/FCF Ratio

MNPRN/A

NGNEN/A

EV/FCF

MNPR-39.10x

NGNE-4.66x

PEG Ratio

MNPRN/A

NGNEN/A

Forward P/E (NTM)

MNPRN/A

NGNEN/A

Forward P/S (NTM)

MNPR48.37x

NGNEN/A

Revenue (TTM)

MNPR$0

NGNE$0

Revenue Growth (YoY)

MNPRN/A

NGNEN/A

Forward Rev Growth

MNPR327.6%

NGNE127.3%

Gross Margin (TTM)

MNPR0.0%

NGNE0.0%

Operating Margin (TTM)

MNPR0.0%

NGNE0.0%

EBITDA Margin (TTM)

MNPR0.0%

NGNE0.0%

Net Margin (TTM)

MNPR0.0%

NGNE0.0%

FCF Margin (TTM)

MNPRN/A

NGNEN/A

Net Income (TTM)

MNPR$-18M

NGNE$-46M

FCF (TTM)

MNPR$-12M

NGNE$-88M

EPS (TTM)

MNPR-$2.09

NGNE$0.00

ROE (TTM)

MNPR-1308.0%

NGNE-2527.0%

ROA (TTM)

MNPR-1279.0%

NGNE-2325.0%

ROIC (TTM)

MNPR-1308.0%

NGNE-2527.0%

Cash

MNPR$53M

NGNE$112M

Debt

MNPR$0

NGNE$8K

Net Cash/Debt

MNPR$53M

NGNE$112M

Current Ratio (TTM)

MNPR33.56x

NGNE10.64x

Quick Ratio (TTM)

MNPR33.56x

NGNE10.53x

Debt/Equity (TTM)

MNPR0.00x

NGNE0.00x

Debt/Assets (TTM)

MNPR0.0%

NGNE0.0%

Interest Coverage (TTM)

MNPRN/A

NGNEN/A

Net Debt/EBITDA (TTM)

MNPR0.00x

NGNE0.00x

Beta

MNPR1.54

NGNE1.71

52W Performance

MNPR-19.9%

NGNE2.2%

YTD Performance

MNPR19.6%

NGNE31.0%

% from 52W High

MNPR-36.7%

NGNE-39.5%

% from 52W Low

MNPR57.7%

NGNE65.7%

Asset Turnover (TTM)

MNPR0.00x

NGNE0.00x

FCF Yield (TTM)

MNPR-2.3%

NGNE-16.8%

Earnings Yield (TTM)

MNPR-3.4%

NGNE-8.8%

Dividend Yield (TTM)

MNPRN/A

NGNEN/A

Rule of 40

MNPR0.0

NGNE0.0

EV/GP/RG

MNPRN/A

NGNEN/A

Ticker research

View MNPR research View NGNE research

Metric	MNPR Monopar Therapeutics Inc	NGNE Neurogene Inc
Market & Valuation
Market Cap	$529M	$521M
Enterprise Value	$476M	$409M
Price	$78.96	$26.40
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	4.00x	2.36x
P/FCF Ratio	N/A	N/A
EV/FCF	-39.10x	-4.66x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	48.37x	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	327.6%	127.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-18M	$-46M
FCF (TTM)	$-12M	$-88M
EPS (TTM)	-$2.09	$0.00
ROE (TTM)	-1308.0%	-2527.0%
ROA (TTM)	-1279.0%	-2325.0%
ROIC (TTM)	-1308.0%	-2527.0%
Financial Health
Cash	$53M	$112M
Debt	$0	$8K
Net Cash/Debt	$53M	$112M
Current Ratio (TTM)	33.56x	10.64x
Quick Ratio (TTM)	33.56x	10.53x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.54	1.71
52W Performance	-19.9%	2.2%
YTD Performance	19.6%	31.0%
% from 52W High	-36.7%	-39.5%
% from 52W Low	57.7%	65.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-2.3%	-16.8%
Earnings Yield (TTM)	-3.4%	-8.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View MNPR research	View NGNE research

Valuation

P/S Ratio

MNPR

0.00x

NGNE

0.00x

EV/FCF

MNPR

-39.10x

NGNE

-4.66x

Growth & revenue

Forward Revenue Growth

MNPR

327.6%

NGNE

127.3%

Profitability & performance

Gross Margin

MNPR

0.0%

NGNE

0.0%

ROE

MNPR

-1308.0%

NGNE

-2527.0%

FCF Yield %

MNPR

-2.3%

NGNE

-16.8%

52-Week Performance

NGNE

2.2%

MNPR

-19.9%

Detailed metrics comparison

MNPR

Monopar Therapeutics Inc

NGNE

Neurogene Inc

Market Cap

MNPR$529M

NGNE$521M

Enterprise Value

MNPR$476M

NGNE$409M

Price

MNPR$78.96

NGNE$26.40

P/E Ratio

MNPRN/A

NGNEN/A

P/S Ratio

MNPR0.00x

NGNE0.00x

EV/Sales

MNPR0.00x

NGNE0.00x

EV/EBITDA

MNPR0.00x

NGNE0.00x

P/B Ratio

MNPR4.00x

NGNE2.36x

P/FCF Ratio

MNPRN/A

NGNEN/A

EV/FCF

MNPR-39.10x

NGNE-4.66x

PEG Ratio

MNPRN/A

NGNEN/A

Forward P/E (NTM)

MNPRN/A

NGNEN/A

Forward P/S (NTM)

MNPR48.37x

NGNEN/A

Revenue (TTM)

MNPR$0

NGNE$0

Revenue Growth (YoY)

MNPRN/A

NGNEN/A

Forward Rev Growth

MNPR327.6%

NGNE127.3%

Gross Margin (TTM)

MNPR0.0%

NGNE0.0%

Operating Margin (TTM)

MNPR0.0%

NGNE0.0%

EBITDA Margin (TTM)

MNPR0.0%

NGNE0.0%

Net Margin (TTM)

MNPR0.0%

NGNE0.0%

FCF Margin (TTM)

MNPRN/A

NGNEN/A

Net Income (TTM)

MNPR$-18M

NGNE$-46M

FCF (TTM)

MNPR$-12M

NGNE$-88M

EPS (TTM)

MNPR-$2.09

NGNE$0.00

ROE (TTM)

MNPR-1308.0%

NGNE-2527.0%

ROA (TTM)

MNPR-1279.0%

NGNE-2325.0%

ROIC (TTM)

MNPR-1308.0%

NGNE-2527.0%

Cash

MNPR$53M

NGNE$112M

Debt

MNPR$0

NGNE$8K

Net Cash/Debt

MNPR$53M

NGNE$112M

Current Ratio (TTM)

MNPR33.56x

NGNE10.64x

Quick Ratio (TTM)

MNPR33.56x

NGNE10.53x

Debt/Equity (TTM)

MNPR0.00x

NGNE0.00x

Debt/Assets (TTM)

MNPR0.0%

NGNE0.0%

Interest Coverage (TTM)

MNPRN/A

NGNEN/A

Net Debt/EBITDA (TTM)

MNPR0.00x

NGNE0.00x

Beta

MNPR1.54

NGNE1.71

52W Performance

MNPR-19.9%

NGNE2.2%

YTD Performance

MNPR19.6%

NGNE31.0%

% from 52W High

MNPR-36.7%

NGNE-39.5%

% from 52W Low

MNPR57.7%

NGNE65.7%

Asset Turnover (TTM)

MNPR0.00x

NGNE0.00x

FCF Yield (TTM)

MNPR-2.3%

NGNE-16.8%

Earnings Yield (TTM)

MNPR-3.4%

NGNE-8.8%

Dividend Yield (TTM)

MNPRN/A

NGNEN/A

Rule of 40

MNPR0.0

NGNE0.0

EV/GP/RG

MNPRN/A

NGNEN/A

Ticker research

View MNPR research View NGNE research

Metric	MNPR Monopar Therapeutics Inc	NGNE Neurogene Inc
Market & Valuation
Market Cap	$529M	$521M
Enterprise Value	$476M	$409M
Price	$78.96	$26.40
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	4.00x	2.36x
P/FCF Ratio	N/A	N/A
EV/FCF	-39.10x	-4.66x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	48.37x	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	327.6%	127.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-18M	$-46M
FCF (TTM)	$-12M	$-88M
EPS (TTM)	-$2.09	$0.00
ROE (TTM)	-1308.0%	-2527.0%
ROA (TTM)	-1279.0%	-2325.0%
ROIC (TTM)	-1308.0%	-2527.0%
Financial Health
Cash	$53M	$112M
Debt	$0	$8K
Net Cash/Debt	$53M	$112M
Current Ratio (TTM)	33.56x	10.64x
Quick Ratio (TTM)	33.56x	10.53x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.54	1.71
52W Performance	-19.9%	2.2%
YTD Performance	19.6%	31.0%
% from 52W High	-36.7%	-39.5%
% from 52W Low	57.7%	65.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-2.3%	-16.8%
Earnings Yield (TTM)	-3.4%	-8.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View MNPR research	View NGNE research